TetraLogic Ends Birinapant MDS Trial After No Clinical Benefit Seen Over Placebo
• By Sten Stovall
Generate a summary of this article
Listen to this article
TetraLogic Pharmaceuticals Corp has ended a placebo controlled Phase II study of birinapant co-administered with azacitidine in first line patients suffering from the blood disorder myelodysplastic syndromes (MDS) after the SMAC-mimetic failed to show any clinical benefit over placebo.
TetraLogic Pharmaceuticals Corp has ended a placebo controlled Phase II study of birinapant co-administered with azacitidine in first line patients suffering from the blood disorder myelodysplastic syndromes (MDS) after the SMAC-mimetic failed to show any clinical benefit over placebo.
Downbeat Birinapant Data
Keep up with the top pharma business news of the week. On the go.
New pivotal data on Regeneron and Sanofi’s antibody in chronic urticaria are underwhelming, though probably sufficient for approval. A green light may beckon in bullous pemphigoid, too.
The Danish firm’s dermatology products have made significant strides in the past six months, leading to an upwards revision of its sales forecast for full-year 2024.
TMB-001, a topical formulation of isotretinoin, missed its primary endpoint in the ASCEND study and will not be filed for approval. Leo is turning its attention to hand eczema and dealmaking.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.